Jean Davignon

Q: What Schools Are Affiliated With Jean Davignon

Jean Davignon is affiliated with the following schools: University of California, San Francisco, Burgundy - Franche-Comté University Group, Université Laval, University of Innsbruck, McGill University, Université de Montréal, University of British Columbia

Jean Davignon's AcademicInfluence.com Rankings

Jean Davignon

Philosophy

#4671

World Rank

#7278

Historical Rank

Logic

#2081

World Rank

#2988

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Jean Davignon Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Jean Davignon, is a Canadian physician, medical researcher, and academic. Born in Montreal, Quebec, he received his Doctor of Medicine from the Université de Montréal in 1958 and a Master of Science degree in 1960 from McGill University.

(See a Problem?)

Jean Davignon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Role of Endothelial Dysfunction in Atherosclerosis (2004) (2324)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. (2006) (1952)
Apolipoprotein E polymorphism and atherosclerosis. (1988) (1435)
Apolipoprotein E polymorphism and Alzheimer's disease (1993) (1001)
Beneficial Cardiovascular Pleiotropic Effects of Statins (2004) (768)
Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. (1985) (728)
Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia (2004) (596)
Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. (1992) (456)
Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. (1990) (448)
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. (1996) (422)
Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte‐specific low‐density lipoprotein receptor degradation and critical role in mouse liver regeneration (2008) (360)
Common low-density lipoprotein receptor mutations in the French Canadian population. (1990) (304)
Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. (1987) (286)
The interaction of cholesterol absorption and cholesterol synthesis in man. (1969) (262)
Low-density lipoprotein-independent effects of statins. (1999) (243)
Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. (1999) (241)
Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. (1996) (224)
Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. (1993) (220)
A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. (1982) (219)
A new method for measurement of total plasma PCSK9: clinical applications (2010) (216)
Apolipoprotein E and atherosclerosis: insight from animal and human studies. (1999) (215)
Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. (2009) (203)
The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. (1995) (194)
Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease (1998) (193)
Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. (1995) (189)
Oxidative Insults Are Associated with Apolipoprotein E Genotype in Alzheimer's Disease Brain (2000) (185)
Current and future treatment of hyperlipidemia: the role of statins. (1998) (184)
Apolipoprotein E phenotyping with a single gel method: application to the study of informative matings. (1983) (181)
Usefulness of chromic oxide as an internal standard for balance studies in formula-fed patients and for assessment of colonic function. (1968) (170)
Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. (1995) (167)
Homozygous Familial Hypercholesterolemia among French Canadians in Quebec Province (1989) (167)
Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. (2004) (162)
Effect of statin withdrawal on frequency of cardiac events after vascular surgery. (2007) (158)
Residual macrovascular risk in 2013: what have we learned? (2014) (157)
Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib†, ‡ (2015) (152)
Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia (1993) (150)
Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. (1999) (148)
Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. (1991) (143)
Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent (1999) (131)
The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. (1993) (126)
Hyperhomocysteinemia induced by folic acid deficiency and methionine load--applications of a modified HPLC method. (1996) (123)
Triglycerides: a risk factor for coronary heart disease. (1996) (123)
Dietary cholesterol and egg yolks: not for patients at risk of vascular disease. (2010) (122)
The role of potatoes and potato components in cardiometabolic health: A review (2013) (115)
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. (2000) (113)
Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease. (1995) (111)
Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. (2011) (108)
Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. (1997) (106)
Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation (2012) (101)
Apolipoprotein E and atherosclerosis: beyond lipid effect. (2004) (99)
Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain. (2001) (97)
Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. (1996) (95)
Apolipoprotein E, synaptic plasticity and Alzheimer's disease. (1995) (93)
Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. (1994) (92)
Canadian Cardiovascular Society position statement on familial hypercholesterolemia. (2014) (91)
Oxidative modification of lipoprotein(a) and the effect of β-carotene (1992) (90)
Apolipoprotein E Genotype and Gender Influence Response to Tacrine Therapy a (1996) (89)
Oxidative stress leads to cholesterol accumulation in vascular smooth muscle cells. (1999) (88)
Pleiotropic effects of pitavastatin (2011) (88)
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. (2008) (87)
Most biological effects of zinc deficiency corrected by γ-linolenic acid (18: 3ω6) but not by linoleic acid (18: 2ω6) (1982) (86)
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. (2001) (86)
Apolipoprotein E polymorphism and atherosclerosis: insight from a study in octogenarians. (1988) (84)
Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. (2009) (81)
β‐Amyloid Peptides Increase the Binding and Internalization of Apolipoprotein E to Hippocampal Neurons (1998) (80)
Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. (1999) (79)
The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis (2010) (78)
Identification of a second “French Canadian” LDL receptor gene deletion and development of a rapid method to detect both deletions (1989) (78)
Egg yolk consumption and carotid plaque. (2012) (78)
Acute influence of smoking on platelet behaviour, endothelium and plasma lipids and normalization by aspirin. (1992) (76)
Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia. (1977) (76)
Apolipoprotein E polymorphism and plasma cholesterol response to probucol. (1987) (75)
Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I. (1998) (73)
The antioxidant effects of statins (2004) (72)
Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. (2009) (71)
HMG-CoA reductase inhibitors: a look back and a look ahead. (1992) (68)
Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health. (2003) (67)
Patterns of association between genetic variability in apolipoprotein (apo) B, apo AI-CIII-AIV, and cholesterol ester transfer protein gene regions and quantitative variation in lipid and lipoprotein traits: influence of gender and exogenous hormones. (1992) (67)
PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia: A Cross-Sectional Cohort Study (2014) (65)
Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. (1997) (64)
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. (2004) (63)
Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects. (1984) (63)
Moderate intake of n-3 fatty acids is associated with stable erythrocyte resistance to oxidative stress in hypertriglyceridemic subjects. (2001) (60)
Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-specific effects. (1994) (59)
Prevalence of alleles encoding defective lipoprotein lipase in hypertriglyceridemic patients of French Canadian descent. (1995) (58)
Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. (1989) (57)
Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. (1998) (57)
Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. (1999) (56)
Molecular Analysis of Human Prorenin Prosegment Variants in Vitro and in Vivo(*) (1995) (56)
Sources of interindividual variation in the quantitative levels of apolipoprotein B in pedigrees ascertained through a lipid clinic. (1988) (55)
Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations (2013) (54)
Apolipoprotein E and Low‐Density Lipoprotein Binding and Internalization in Primary Cultures of Rat Astrocytes: Isoform‐Specific Alterations (1996) (54)
Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group. (1999) (54)
Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. (2000) (53)
In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. (1992) (53)
Psychotropic drugs as potential antitumor agents: a selective screening study. (1978) (53)
Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE. (1997) (52)
Familial hypercholesterolemia in French-Canadians: taking advantage of the presence of a "founder effect". (1993) (52)
Plasma phospholipids in the different types of primary hyperlipoproteinemia. (1972) (50)
The effect of insulin on circulating PCSK9 in postmenopausal obese women. (2014) (50)
Ongoing Clinical Trials of the Pleiotropic Effects of Statins (2005) (49)
Influence of probucol on enhanced LDL oxidation after fish oil treatment of hypertriglyceridemic patients. (1993) (49)
Effect of regular exercise on homocysteine concentrations: the HERITAGE Family Study (2006) (48)
Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO). (2005) (47)
Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. (1996) (45)
Identification of a &ggr;-Interferon-Responsive Element in the Promoter of the Human Macrophage Scavenger Receptor A Gene (2001) (45)
G-->A substitution at position -75 of the apolipoprotein A-I gene promoter. Evidence against a direct effect on HDL cholesterol levels. (1995) (45)
Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians (1992) (44)
Genetics of lipoprotein disorders. (1998) (43)
Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor. (1990) (43)
A PCSK9 variant and familial combined hyperlipidaemia (2008) (43)
Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. (2001) (43)
Severe familial HDL deficiency in French-Canadian kindreds. Clinical, biochemical, and molecular characterization. (1995) (43)
Increased Frequency of Apo E-ND phenotype and hyperapobeta-lipoproteinemia in normolipidemic subjects with xanthelasmas of the eyelids. (1982) (42)
Estimation of Hardy-Weinberg and pairwise disequilibrium in the apolipoprotein AI-CIII-AIV gene cluster. (1991) (42)
Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia. (1991) (42)
Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects DOI 10.1194/jlr.M200055-JLR200 (2002) (42)
Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools (2007) (42)
Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state. (2000) (41)
PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. (2015) (41)
Plasma Lipids and Lipoproteins in Friedreich's Ataxia and Familial Spastic Ataxia — Evidence for an Abnormal Composition of High Density Lipoproteins (1978) (40)
Two naturally occurring mutations at the first and second bases of codon aspartic acid 156 in the proposed catalytic triad of human lipoprotein lipase. In vivo evidence that aspartic acid 156 is essential for catalysis. (1992) (40)
Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians. (1997) (40)
Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype. (2013) (39)
Geographic distribution of French‐Canadian low‐density lipoprotein receptor gene mutations in the Province of Quebec (1997) (39)
Expression of apolipoprotein B epitopes in lipoproteins. Relationship to conformation and function. (1988) (38)
Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations. (2000) (38)
Apolipoprotein E limits oxidative stress‐induced cell dysfunctions in human adipocytes (2009) (36)
High-density lipoprotein particles in octogenarians. (1991) (36)
Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells. (2004) (36)
Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect. (1996) (35)
Effects of glucagon on plasma lipids in different types of primary hyperlipoproteinemia. (1974) (35)
Role of zinc in linoleic acid desaturation and prostaglandin synthesis. (1981) (35)
Interaction of lecithin:cholesterol acyltransferase (LCAT).alpha 2-macroglobulin complex with low density lipoprotein receptor-related protein (LRP). Evidence for an alpha 2-macroglobulin/LRP receptor-mediated system participating in LCAT clearance. (2001) (34)
Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component. (1990) (34)
Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism. (2003) (33)
Oxidative modification of Lp(a) causes changes in the structure and biological properties of apo(a). (1994) (33)
Oxidative modification of lipoprotein(a) and the effect of beta-carotene. (1992) (32)
Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. (1992) (32)
Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy. (1991) (32)
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. (1998) (32)
Apo E Allele Frequency in Primary Endogenous Hypertriglyceridemia (Type IV) with and without Hyperapobetalipoproteinemia (1985) (31)
Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism. (2003) (31)
Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.D300041-JLR200 (2004) (31)
Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects. (1991) (30)
A new method for measurement of total plasma PCSK 9 : clinical applications (2009) (30)
Effect of fenofibrate treatment on type III hyperlipoproteinemia. (1987) (30)
Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia. (1991) (30)
Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene. (1994) (30)
[Mechanisms of action of statins and their pleiotropic effects]. (2001) (29)
Impact of apolipoprotein E genotype variation on means, variances, and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians. (1995) (29)
Plasma lipids and lipoprotein patterns in angiographically graded atherosclerosis of the legs and in coronary heart disease. (1977) (28)
Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing a 'null' LDL-receptor gene defect. (1996) (28)
Probucol protects lipoprotein (a) against oxidative modification. (1992) (28)
Characterization of inherited scavenger receptor overexpression and abnormal macrophage phenotype in a normolipidemic subject with planar xanthomas. (1996) (27)
Simple, reproducible procedure for selective measurement of lipoprotein lipase and hepatic lipase. (1983) (27)
Secreted apolipoprotein E reduces macrophage‐mediated LDL oxidation in an isoform‐dependent way (2003) (26)
Fatty Acid Profile of Major Lipid Classes in Plasma Lipoproteins of Patients with Friedreich's Ataxia — Demonstration of a Low Linoleic Acid Content most evident in the Cholesterol-Ester Fraction (1979) (26)
Pharmacokinetics of clofibrate in familial hypercholesterolemia. (1977) (26)
Genetic structure and the search for genotype-phenotype relationships: an example from disequilibrium in the Apo B gene region. (1991) (26)
High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes (2009) (25)
(Arch. Intern. Med., 137:1429-1434)Diet and probucol in lowering cholesterol concentrations (1977) (25)
An application of a model for a genotype‐dependent relationship between a concomitant (age) and a quantitative trait(LDL cholesterol)in pedigree data (1984) (24)
An improved radiological method for the evaluation of Achilles tendon xanthomatosis. (1973) (24)
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia DOI 10.1194/jlr.M200016-JLR200 (2002) (24)
Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins. (1995) (24)
Pro‐oxidant effects of 7‐hydroperoxycholest‐5‐en‐3β‐ol on the copper‐initiated oxidation of low density lipoprotein (1995) (23)
Plasma cholesterol esterification in normal and hyperlipoproteinemic subjects. (1973) (23)
Occurrence and biological effects of cholesteryl sulfate on blood platelets. (1995) (23)
In vitro factors affecting the concentration of gamma-LpE (gamma-LpE) in human plasma. (1998) (23)
Gene set enrichment analyses revealed several affected pathways in Niemann-pick disease type C fibroblasts. (2007) (22)
The cardioprotective effects of statins (2004) (22)
Apolipoprotein E polymorphism in a French Canadian population of northeastern Quebec: allele frequencies and effects on blood lipid and lipoprotein levels. (1996) (22)
Impact of a common mutation of the LDL receptor gene, in French‐Canadian patients with familial hypercholesterolemia, on means, variances and correlations among traits of lipid metabolism (1995) (21)
Blood lipids and coronary heart disease. (1978) (21)
Advances in drug treatment of dyslipidemia: focus on atorvastatin. (1998) (20)
Association of apolipoprotein E with α2-macroglobulin in human plasma (1998) (20)
Characterization of a new LCAT mutation causing familial LCAT deficiency (FLD) and the role of APOE as a modifier gene of the FLD phenotype. (2009) (20)
Association of apolipoprotein E with alpha2-macroglobulin in human plasma. (1998) (20)
Heroin: Stability and formulation approaches (1983) (19)
Analytical isoelectric focusing with immobilized pH gradients of human apolipoprotein E from very low density lipoproteins and total plasma. (1990) (19)
The lipid hypothesis. Pathophysiological basis. (1978) (19)
Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects. (1998) (19)
Beta-blockers and changes in lipoprotein fractions. (1980) (18)
Emphasis on pleiotropic effects, a new paradigm shift? (2004) (18)
Medical management of hyperlipidemia and the role of probucol. (1986) (18)
Involvement of Oxysterols and Lysophosphatidylcholine in the Oxidized LDL–Induced Impairment of Serum Albumin Synthesis by HEPG2 Cells (2000) (17)
Cholesteryl sulfate: measurement with beta-sitosteryl sulfate as an internal standard. (1981) (17)
Heterogeneity on familial hyperlipoproteinemia type II on the basis of fasting plasma triglyceride-cholesterol ratio and plasma cholesterol response to ethyl p-chlorophenoxyisobutyrate. (1971) (17)
White Adipose Tissue Apolipoprotein C-I Secretion in Relation to Delayed Plasma Clearance of Dietary Fat in Humans (2012) (17)
Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. (1995) (17)
Severe hypoalphalipoproteinemia induced by a combination of probucol and clofibrate. (1986) (16)
EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs. (1988) (16)
Tiazofurin: A new antitumor agent (2004) (16)
Lecithin: Cholesterol Acyltransferase Activity and Fatty Acid Composition of Erythrocyte Phospholipids in Friedreich's Ataxia (1980) (16)
Sources of variation in plasma lipid and lipoprotein traits in a sample selected for health. (1999) (16)
Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia. (1993) (15)
Cladistic analysis of the apolipoprotein AI‐CIH‐AIV gene cluster using a healthy French Canadian sample. I. Haploid analysis (1995) (15)
Eruptive and tubero-eruptive xanthomas of the skin arising on sites of prior injury. Two case reports. (1988) (15)
2.C.5 The pleiotropic effects of drugs affecting lipid metabolism (1997) (14)
New methods for rapid detection of low-density lipoprotein receptor and apolipoprotein B gene mutations causing familial hypercholesterolemia. (1995) (14)
Association of an exon 3 mutation (Trp66-->Gly) of the LDL receptor with variable expression of familial hypercholesterolemia in a French Canadian family. (1997) (14)
Lipoprotein lipase gene mutations in coronary artery disease. (1998) (14)
Dapsone-induced methemoglobinemia in a patient with P. carinii pneumonia and AIDS. (1987) (14)
Pharmaceutical assessment of amygdalin (Laetrile) products. (1978) (14)
Usefulness of probucol in treating primary hypercholesterolemia. (1980) (13)
Apolipoprotein E2(Arg158→Cys) Frequency in a Hyperlipidemic French‐Canadian Population of Apolipoprotein E2/2 Subjects: Determination by Synthetic Oligonucleotide Probes (1989) (13)
Apolipoprotein B‐48 and B‐100 Very Low Density Lipoproteins: Comparison in Dysbetalipoproteinemia (Type III) and Familial Hypertriglyceridemia (Type IV) (1985) (13)
Cardioprotective and other emerging effects of statins (2004) (13)
The effect of portacaval shunt on plasma lipids and lipoproteins in swine. (1977) (13)
Tendon xanthomas associated with cholestanolosis and hyperapobetalipoproteinemia. (1986) (13)
Effect of acute and chronic administration of calcitonin on serum glucose in patients with Paget's disease of bone. (1980) (12)
Short-term response to dietary counseling of hyperlipidemic outpatients of a lipid clinic. (1994) (12)
A muclticenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia (1990) (12)
Determination of Δ9-tetrahydrocannabinol in pharmaceutical vehicles by high-performance liquid chromatography vehicles by high-performance liquid chromatography (1981) (12)
Most biological effects of zinc deficiency corrected by gamma-linolenic acid (18: 3 omega 6) but not by linoleic acid (18: 2 omega 6). (1982) (12)
Fatty acid profile of plasma lipid classes in coronary heart disease, in primary hyperlipoproteinemias, and in healthy subjects. (1973) (12)
Lipolytic and hypocalcemic effects of sheep beta-lipotropic hormone. (1970) (12)
Effect of methyl linoleate administration on phospholipid fatty acid composition and osmotic fragility of erythrocytes in essential fatty acid deficient rats. (1983) (12)
The lipid content of the diabetic kidney of the rat. (1984) (12)
Failure to isolate cortisol from a pheochromocytoma. (1960) (12)
Association of Lp(a) rather than integrally-bound apo(a) with triglyceride-rich lipoproteins of human subjects. (1997) (11)
Genealogy and regional distribution of lipoprotein lipase deficiency in French-Canadians of Quebec. (1993) (11)
Lipid and lipoprotein secretion following portacaval shunt in swine. (1978) (11)
Ultracentrifugal demonstration of floating beta lipoproteins in type 3 hyperlipoproteinemia. Diagnostic value. (1971) (11)
Apolipoprotein(a) is present in the triglyceride-rich fraction in type IV hypertriglyceridemia. (1993) (11)
Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk (2016) (11)
Advances in lipid-lowering therapy in atherosclerosis. (2001) (10)
WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects[S] (2016) (10)
Parallel biochemical and histochemical studies of an adrenocortical adenoma from a patient with primary aldosteronism. (1961) (10)
Risks for hyperlipidemia. (1986) (10)
Gene set enrichment analysis reveals several globally affected pathways due to SKI-1/S1P inhibition in HepG2 cells. (2007) (10)
Primary Hyperlipidemias: An Atlas Of Investigation And Diagnosis (2007) (10)
Effect of Atorvastatin on ApoE and ApoC-I Synthesis and Secretion by THP-1 Macrophages (2003) (10)
Dissolution and absorption of the antineoplastic agent ellipticine. (1978) (9)
Apolipoproteins and cardiovascular risk: Genetics and epidemiology (1985) (9)
Immunochemical evidence that human apoB differs when expressed in rodent versus human cells Published, JLR Papers in Press, December 16, 2002. DOI 10.1194/jlr.M200413-JLR200 (2003) (9)
Cyclic Fluctuations of Plasma Cholesterol in the Female Miniature Swine and Its Relationship to Progesterone Secretion 1 (1977) (9)
Angiotensin converting enzyme insertion/deletion polymorphism in French Canadian subjects with premature coronary artery disease. (1998) (9)
Effect of exercise training on in vitro LDL oxidation and free radical-induced hemolysis: the HERITAGE Family Study. (2007) (9)
Erythrocyte Membrane Lipids in Fríedreich's Ataxia (1979) (9)
Egg yolk consumption, smoking and carotid plaque: reply to letters to the Editor by Sean Lucan and T Dylan Olver et al. (2013) (8)
Post-transcriptional regulation of apoC-I synthesis and secretion in human HepG2 cells. (2005) (8)
Roentgenological evaluation of Achilles-tendon xanthomatosis. (1971) (8)
Cardiovascular risk factors and lipoprotein profile in French Canadians with premature CAD: impact of the National Cholesterol Education Program II. (1995) (8)
Genetic epidemiology of lipoprotein lipase deficiency in Saguenay-Lac-St-Jean (Québec, Canada). (1992) (8)
Halofenate versus clofibrate in the management of true diabetes insipidus. (1974) (8)
Spiromustine: a new agent entering clinical trials (2004) (8)
Expression of gamma-IFN responsive genes in scavenger receptor over-expressing monocytes is associated with xanthomatosis. (1998) (7)
Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: gender-specific effects (1994) (7)
(Can. J. Neurol. Sci., 04:149-156)Plasma lipids and lipoproteins in Friedreich's ataxia and familial spastic ataxia (1978) (7)
Prevalence of double pre-beta lipoproteinemia in hyperlipidemic patients is influenced by gender, menopausal status, and ApoE phenotype. (1997) (7)
Influence of a triphasic oral contraceptive preparation on plasma lipids and lipoproteins. (1990) (7)
2.W15.1 Different approaches to the detection and quantification of triglyceride-rich lipoprotein remnants (1997) (7)
A phenocopy of type III dysbetalipoproteinemia occurring in a candidate family for a putative apo E receptor defect. (1991) (7)
Evidence for a cholesterol-lowering gene in a French-Canadian kindred with familial hypercholesterolemia (1995) (7)
ACAT activity in freshly isolated human mononuclear cell homogenates from hyperlipidemic subjects. (1992) (7)
Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? A Perspective from the Residual Risk Reduction Initiative (R3i) (2014) (7)
Enhanced susceptibility of cholesteryl sulfate‐enriched low density lipoproteins to copper‐mediated oxidation (1995) (6)
Plasma methyl sterol sulfates in familial hypercholesterolemia after partial ileal bypass. (1982) (6)
Guanethidine administration in 28 hypertensive patients. (1960) (6)
Atherosclerosis X : proceedings of the 10th International Symposium on Atherosclerosis, Montréal, October 9-14, 1994 (1995) (6)
Development of hyperlipidemia associated with increased lipolytic response of isolated adipose tissue cells following prolonged stimulation by an ectopic pituitary tumor. (1978) (6)
Clearance of plasma proprotein convertase subtilisin/kexin 9 by low-density lipoprotein apheresis. (2014) (6)
Unexpected Consequences of Deletion of the First Two Repeats of the Ligand-binding Domain from the Low Density Lipoprotein Receptor (1995) (6)
Intrathecal injections--a review of pharmaceutical factors. (1977) (6)
Interaction of Two Lipid Disorders in a Large French‐Canadian Kindred (1983) (6)
Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women. (2017) (5)
Studies on the in vitro production of corticosteroids by adrenal glands from normotensive individuals and hypertensive patients. (1962) (5)
Prospects for drug therapy for hyperlipoproteinaemia. (1995) (5)
Net esterification in vitro of plasma cholesterol in human primary hyperlipidemia (1971) (5)
The relation between triglyceride synthesis in peripheral tissues and postprandial plasma triglyceride levels: preliminary evidence of a role for acylation stimulating protein. (1992) (5)
Plasma Lipoprotein Lipase and Hepatic Lipase Activities in Friedreich’s Ataxia (1982) (5)
(Atherosclerosis, 41:193-207)Most biological effects of zinc deficiency corrected by gamma-linolenic acid (18:3n-6) but not by linoleic acid (18:2n-6) (1981) (5)
[Phenotype of apolipoprotein E, hyperlipidemia and atherosclerosis]. (1988) (5)
Severe oily ichthyosis in monozygotic twins mimicking Chanarin-Dorfman syndrome but not associated with a mutation of the CGI58 gene. (2006) (5)
Atherogenic dyslipidemias: Disorders of apolipoprotein E isoforms (1989) (4)
Time to take a stance on cholesterol and lipoproteins. (1988) (4)
Triglyceride-Rich Remnant Lipoproteins Detection , Quantification , and Characterization of Potentially Atherogenic (1999) (4)
Plasma Cholesteryl Sulfate in Friedreich's ataxia (1984) (4)
Abstract 124: Increased Selective Clearance of Cholesteryl-Ester in Patients with Rheumatoid Arthritis is Reversed by Treatment with Tofacitinib (2013) (4)
Experience with probucol in the treatment of hypercholesterolemia. (1982) (4)
Identification of the patient at risk in the physician's office and drug management of dyslipoproteinemia. (1988) (4)
A lipid clinic associated with a research laboratory working on dyslipoproteinemias and atherosclerosis. (1996) (4)
Formulation of three nitrosoureas for intravenous use. (1973) (4)
Fish-oil supplementation reduces Ip(a) concentrations in type III dysbetalipoproteinemia. (1992) (4)
(Can. J. Physiol. Pharmacol., 58:767-771)Liver lipid metabolism and effect of cholesterol-lowering agents in the hyperlipidemia induced in rats by implantation of the pituitary derived MtT-F4 tumor (1980) (4)
Differential effects of oxidized LDL on apolipoprotein AI and B synthesis in HepG2 cells. (2006) (4)
Genetics and molecular biology: Editorial overview (1992) (4)
Hyperlipoproteinemia induced by a transplantable pituitary tumor in the rat. (1979) (4)
Pseudo type III dyslipoproteinemia is associated with normal fibroblast lipoprotein receptor activity. (1997) (3)
Effect of Regular Aerobic Exercise on Plasma Homocysteine Concentrations: The HERITAGE Family Study (2004) (3)
Tissue Lipids in Acute Acrylamide Intoxicated Rats (1982) (3)
Changes in total and central fat mass after a hypocaloric diet associate with changes of apoC-I in postmenopausal obese women. (2014) (3)
Delta-9-tetrahydrocannabinol: comments on antiemetic trials. (1981) (3)
Some Aspects of Sensitivity and Resistance to the Cholesterol Lowering Effect of Clofibrate (1977) (3)
[Women and ischemic cardiopathy]. (1989) (3)
Relationship between plasma cholesterol levels and cholesterol esterification in isolated human mononuclear cells. (1990) (3)
Comparison of three fibric acid derivatives in hypertriglyceridemic patients, effect on Lp(a) levels (1994) (3)
Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans Published, JLR Papers in Press, July 16, 2003. DOI 10.1194/jlr.M300209-JLR200 (2003) (2)
Effect of clofibrate treatment on chronic hyperlipidemia induced by an ACTH-producing tumor. (1977) (2)
Cholesterol turnover in miniature swine with a portacaval shunt (1979) (2)
Phenotypic heterogeneity associated with defective apolipoprotein B-100 and occurrence of the familial hypercholesterolemia phenotype in the absence of an LDL-receptor defect within a Canadian kindred (1992) (2)
Effect of fish oil supplementation on plasma homocysteine levels in patients with type III and type IV hypertriglyceridemia (1994) (2)
Studies of a Large French-Canadian Kindred with Two Forms of Hyperlipoproteinemia (1980) (2)
Plasma carnitine and lipid-lowering drugs. (1985) (2)
Determination of delta 9-tetrahydrocannabinol in pharmaceutical vehicles by high-performance liquid chromatography. (1981) (2)
2.P.41 Two year treatment experience with high dose atorvastatin (1997) (2)
4.P.241 Plasma remnant-like particle (RLP) lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects (1997) (2)
Effects of Ketanserin on Lipids, Lipoproteins, and Plasma Atrial Natriuretic Factor in Patients with Essential Hypertension (1990) (2)
Apolipoprotein E Uptake is Increased by Beta-Amyloid Peptides and Reduced by Blockade of the LDL Receptor (1996) (2)
ApoE phenotype influences plasma ASP in hyperapoB subjects. (2003) (2)
Xanthelasma palpebrarum and corneal arcus in octogenarians. (1987) (2)
Two new large deletions in the low density lipoprotein receptor (LDLR) gene not revealed by PCR-based molecular diagnosis of familial hypercholesterolemia. (2008) (2)
Platelet-induced oxidative low density lipoprotein modification (1995) (2)
Interaction of Lecithin:Cholesterol Acyltransferase (LCAT)·α2-Macroglobulin Complex with Low Density Lipoprotein Receptor-related Protein (LRP) (2001) (2)
of Plasma for (2004) (2)
Pseudo type III dyslipoproteinemia is not associated with an identifiable lipoprotein receptor defect (1994) (1)
Investigational Drug Information (1976) (1)
Cyclic nucleotides and platelet aggregation in hypertensive rats with ectopic pituitary tumor. (1980) (1)
Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations (2013) (1)
AHA Conference Report on Cholesterol. Drug therapy. (1989) (1)
Cardiovascular risk factors and lipoprotein profile in premature CAD in French Canadians: impact of the National Cholesterol Education Program II (NCEP II) (1994) (1)
Oxidation of Lipoprotein (a) Particles Increases their Uptake by Macrophages (1992) (1)
Effect of indomethacin treatment on prostaglandin excretion and tissue phospholipid fatty acid composition in rats bearing mammotropic pituitary tumor, MtT-F4. (1986) (1)
[Effect of glucagon on cholesterol esterification and on blood cholesterol levels in normal and hyperlipidemic subjects]. (1973) (1)
Homocyst(e)ine in health and coronary artery disease in French Canadian men and women: relationship with vitamins B12, B6, pyridoxal phosphate and folate (1994) (1)
Platelet-induced oxidative LDL modification (1994) (1)
The LDL receptor is not required for normal catabolism of Lp(a) in humans (1994) (1)
(Can. J. Neurol. Sci., 06:291-294)Erythrocyte membrane lipids in Friedreich's ataxia (1979) (1)
Investigational Drug Information (1979) (1)
Distribution of apolipoprotein E phenotypes in Friedreich's ataxia (1984) (1)
Poster abstractAtorvastatin, a new HMG-CoA reductase inhibitor (HMGRI), is safe and effective in hypertriglyceridemic patients (1994) (1)
Rapid measurement of erythrocyte osmotic fragility. (1984) (1)
Effect of n-3 polyunsaturated fatty acids (PUFAs) on lipid peroxidation, plasma homocysteine levels and antioxidant status in normolipidemic subjects (1995) (1)
An unusual band that binds hemoglobin after ultracentrifugation of hemolyzed plasma for lipoprotein separation. (1989) (1)
Mechanism for National Distribution of Δ9‐Tetrahydrocannabinol (NSC‐134454) (1981) (1)
Effect of acute administration of salmon and human calcitonin on blood urate and renal excretion of uric acid in patients with Paget's disease of bone. (1979) (1)
Fatty acid composition of tissue phospholipids and prostaglandin excretion in hyperlipidemia induced in rats by implantation of the mammotropic pituitary tumor MtT-F4 (1983) (1)
2.P.5 In vitro factors affecting the concentration of gamma-LpE (γ-LpE) in human plasma (1997) (1)
1078 HYPOCHOLESTEROLAEMIA IN CHRONIC HEPATITIS C GENOTYPE 3 INFECTION IS DUE TO BOTH REDUCED CHOLESTEROL PRODUCTION AND INCREASED LDL CLEARANCE (2010) (1)
Investigational Drug Information (1978) (1)
[Lipoproteins and lipid transport]. (1968) (1)
Biochemical and Molecular Actions of Nutrients Synthesis and Secretion of ApoC-I and ApoE during Maturation of Human SW 872 Liposarcoma Cells 1 (2004) (1)
Diagnosis and Cardiovascular Risk Factors in Dysbetalipoproteinemia: a Large Cohort Study* (2014) (1)
Dosage form design of investigational drugs in cancer chemotherapy. (1969) (1)
[Xanthoma and atherosclerosis in the presence of normal plasma lipids]. (1983) (1)
Ultracentrifugal Demonstration of Floating Beta Lipoproteins in Type III Hyperlipoproteinemia (2020) (0)
Indications for lipid-lowering drugs (2011) (0)
Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg13,+ His): association with mild dyslipidemia and double pre-p very low density lipoproteins (2002) (0)
Macrophage Scavenger Receptor A Gene Responsive Element in the Promoter of the Human −-Interferon γ Identification of a Print (2001) (0)
Quebec Cooperative Study of Friedreich ' s Ataxia Tissue Lipids in Acute Acrylamide Intoxicated Rats (2014) (0)
Evidence for a cholesterol-lowering gene unrelated to the LDL receptor in a French Canadian kindred (1994) (0)
[Hypertriglyceridemia induced by carbohydrates in primary hyperlipoproteinemia]. (1977) (0)
[HDL cholesterol profile in 1988]. (1989) (0)
PCSK9 FROM GENE AND VARIANTS TO PROTEIN AND PHENOTYPE (2008) (0)
1.P.187 Induction of STAT1α in scavenger receptor overexpressing monocytes of a normolipidemic with planar xanthomas (1997) (0)
Abstract 20466: HyperapoB Women Have Increased Accumulation of ApoC-I on Triglyceride Rich Lipoproteins and Increased Production of ApoC-I by Adipose Tissue (2010) (0)
4.P.338 Familial HDL deficiency: A cellular cholesterol transport defect (1997) (0)
[Plasma apolipoproteins in dyslipoproteinemias. III. Classical hyperlipemias]. (1978) (0)
[Preliminary study of the characteristics of the blood lipid pattern as related to the presence of the corneal ring in a group of Haitians]. (1975) (0)
Abstract 261: Liver-specific Pcsk9 Knockout And Transgenic Mice (2007) (0)
Impairment of Serum Albumin Synthesis by HEPG 2 Cells Induced − Involvement of Oxysterols and Lysophosphatidylcholine in the Oxidized LDL (2000) (0)
Cholesteryl sulfate-enriched LDL are more susceptible to copper-mediated oxidation (1995) (0)
Hypocholesterolaemia in chronic Hepatitis C virus (HCV) infection – Reduced production or increased LDL clearance? (2010) (0)
1.P.207 Variability in the response to atorvastatin in two siblings homozygote for the same LDL-receptor gene mutation (1997) (0)
Postprandial Lipoproteins and their Relationship to Atherosclerosis and Thrombosis (1996) (0)
Familial hypercholesterolemia: a treatable lethal disease. (1991) (0)
[Non-pharmacologic treatment of hyperlipemia: diet and exercise]. (1989) (0)
Inhibition of sterol regulatory element-binding protein cleavage by the prodomain of human SKI-1 protease (2000) (0)
[Diagnosis and treatment of primary hyperlipidemias]. (1982) (0)
Regulation of the scavenger receptor type A in human blood-derived monocytes (2000) (0)
Drug Therapy Participants (0)
[Discussion on endocrine physiology and intermediary metabolism]. (1968) (0)
Abstract 815: Comparative Atorvastatin Pleiotropic effects (CAP) study (2006) (0)
PO5-109 IDENTIFICATION OF TWO NEW LARGE DELETIONS IN THE LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR) GENE IN THE FRENCH CANADIAN POPULATION (2007) (0)
Indications for lipid-lowering drugs (2005) (0)
Beyond LDL-cholesterol: can further reductions in CAD risk be achieved by considering triglycerides? (1998) (0)
Dietary supplementation with fish oil reduces plasma apo E levels in patients with type III and type IV hypertriglyceridemia (1994) (0)
The Genetics of Lipoprotein Disorders (1996) (0)
PO23-785 LDL-C AND CRP IN ATORVASTATIN TREATED STABLE CORONARY ARTERY DISEASE PATIENTS: THE CAP (COMPARATIVE ATORVASTATIN PLEOTROPIC) EFFECTS STUDY RESULTS (2007) (0)
Morphine acetate. (1980) (0)
3.P.88 Heterogeneous effect of n-3 polyunsaturated fatty acids (PUFAs) on LDL in vitro oxidation in healthy subjects (1997) (0)
Effects of chlorthalidone and metoprolol alone or in combination (logroton) on blood pressure, lipids, lipoproteins and circulating plasma ANF levels in essential hypertension. (1991) (0)
Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: dose formulation. (1972) (0)
Apolipoprotein E and Atherosclerosis (2005) (0)
Precision and long-term stability of newer controls for blood pH and blood gases. (1984) (0)
Abstract: S4-8 EFFECTS OF STATINS (2009) (0)
2.W13.4 An inherited abnormality in monocyte SR expression is associated with planar xanthomas (1997) (0)
Biochemical Synthesis and Secretion of ApoC-I and ApoE during Maturation of Human SW872 Liposarcoma Cells 1 (2004) (0)
Consumption of potatoes and cardiovascular disease risk factors. (2010) (0)
Clinical characteristics of FH patients homozygous for apo E2 (1994) (0)
STATINS AND EZETIMIBE UPREGULATE PLASMA PCSK9 (2008) (0)
[Combined electrophoresis and ultracentrifugation in diagnosis of primary hyperlipidemia]. (1971) (0)
[Plasma apolipoproteins]. (1976) (0)
W08.191 Post-transcriptional regulation of ApoC-I production by cholesterol in HEPG2 cells (2004) (0)
[Detection and treatment of lipid disorders]. (1988) (0)
Gamma-LpE (γ-LpE) concentrations was regulated by cell membranes and phospholipids (2000) (0)
Overproduction of apoE in patients with type III hyperlipoproteinemia and in patients with other forms of hypertriglyceridemia (2000) (0)
Plasma lipoprotein distribution of apolipoprotein E: the quantitative significance of apo E in remnant-sized lipoproteins in normolipidemic and hyperlipidemic subjects (1994) (0)
Effect of fenofibrate on glucose and insulin levels of hypertriglyceridemic non-diabetic subjects (1994) (0)
(Can. J. Physiol. Pharmacol., 62:1274-1278)The lipid content of the diabetic kidney of the rats (1984) (0)
CHARACTERIZATION OF A NEW LCAT MUTATION CAUSING FAMILIAL LCAT DEFICIENCY (FLD) AND THE ROLE OF APOE AS A MODIFIER GENE OF THE FLD PHENOTYPE (2009) (0)
Mechanism for national distribution of delta 9-tetrahydrocannabinol (NSC-134454). (1981) (0)
Canadian Cardiovascular Society Position Statement onFamilial Hypercholesterolemia (2014) (0)
Reply to Letters from Dr Maria Luz Fernandez, Eddie Vos, and Dr Niva Shapira (2011) (0)
(Clin. Chem., 30:336-337)Rapid measurement of erythrocyte osmotic fragility (1984) (0)
genotype and gender of the subjects with Alzheimer ' s disease Treatment outcome of tacrine therapy depends on apolipoprotein (2007) (0)
Mo-P6:409 Preliminary characterization of a French Canadian family with the R237W mutation of PCSK9/NARC1 (2006) (0)
Potential role of oxysterols and lysolecithin in the oxidised LDL-induced decrease in albumin synthesis in HEPG2 cells (2000) (0)
[Clinical evaluation of dexamethasone]. (1959) (0)
[Diagnosis of primary hyperlipidemia]. (1968) (0)
W09.200 Insulin resistance is associated with increased VLDL triglyceride and VLDL apoC-III production (2004) (0)
Severe familial primary hypoalphalipoproteinemia in French Canadian kindred: no association with the apo A-I/C-III/A-IV and A-II gene loci, normal LCAT activity, normal triglyceride levels and lack of clinical manifestations of Tangier Disease (1994) (0)
Quantification of lipoprotein remnants in normolipidemic and hyperlipidemic subjects by measurement of plasma apolipoprotein E concentration in “remnant-sized” lipoproteins (1995) (0)
Quebec Cooperative Study of Friedreich ' s Ataxia Plasma Lipids and Lipoproteins in Friedreich ' s Ataxia and Familial Spastic Ataxia — Evidence for an Abnormal Composition of High Density Lipoproteins (2014) (0)
Round table discussion: practical issues in the management of dyslipidaemic patients. (1996) (0)
[Plasma apoproteins in dyslipoproteinemias. I. The hypolipidemias]. (1977) (0)
Diet, Atherosclerosis, and Endothelial Dysfunction (2003) (0)
Biochemical changes in Friedreich's ataxia. (1979) (0)
Diagnosis and Treatment of Hyperlipidemias (1985) (0)
[Children and dyslipemia]. (1990) (0)
Workshop: Absorbable Drugs (1974) (0)
Cholesteryl ester and lipid biosynthesis are modulated by oxysterols incorporated into smooth muscle cells (1994) (0)
[Primary hyperaldosteronism. A review of the medical literature from 1995 to June 1958]. (1959) (0)
Characterization of VLDL from a kindred with a unique dyslipoproteinemia which mimics Type III (1994) (0)
EFFECTS OF EXERCISE TRAINING ON PLASMA TOTAL HOMOCYSTEINE AND GLUTATHIONE LEVELS: THE HERITAGE FAMILY STUDY (1998) (0)
Omega-3 lipoproteins and atherosclerosis : proceedings of the International Symposium held in Granada (Spain) October 13-15, 1995 (1996) (0)
W16-P-015 Beneficial effect of atorvastatin on plasma and lipoprotein APOC-III metabolism in hyperlipidemic patients (2005) (0)
Genetic screening for familial hypercholesterolemia in french canadians (1994) (0)
Insulin Infusion Acutely Downregulates Circulating PCSK9 in Human (2014) (0)
Experimental hyperlipidemia in rats. (1979) (0)
[Systematic approach to the treatment of hereditary hyperlipidemias]. (1980) (0)
Abstract: 25 UNTANGLING THE LIPID AND NON-LIPID EFFECTS OF STATINS ON CAD RISK (2009) (0)
The Use of Statins in Atherosclerotic Cardiovascular Disease (2004) (0)
(Can. J. Neurol. Sci., 09:181-184)Tissue lipids in acute acrylamide intoxicated rats (1982) (0)
Lipid lowering in patients with coronary artery disease: low density lipoprotein cholesterol and beyond. (1997) (0)
Opposite atherogenic effects of oxidised LDL on apolipoprotein AI and B synthesis in HEPG2 cells (2000) (0)
Differential expression and stability of scavenger receptor isoforms in human monocyte-derived macrophages (1994) (0)
At what level should LDL-cholesterol be reduced for secondary prevention? Rationale and design of the NIH Post-CABG clinical trial (1994) (0)
Studies on a new hypotensive agent: bretylium tosylate. (1960) (0)
Effects of Apolipoprotein E Polymorphism on Plasma Lipoprotein (a) Levels and Cardiovascular Outcomes in Familial Hypercholesterolemia (2014) (0)
Abstract: 1473 PCSK9 IN YOUTH (2009) (0)
The Role of Statins in Dyslipidemia: Making the Difference (1999) (0)
Tu-P7:8 Apolipoprotein E promotes cell proliferation and inhibits maturation of human adipocytes (2006) (0)
4P-1205 Oily ichtyosis is a phenocopy of Chanarin-Dorfman syndrome (2003) (0)
[Plasma apolipoproteins in dyslipoproteinemias. III. LCAT deficiency and other hyperlipidemias]. (1978) (0)
Colt, multicenter capre open label randomized dose-ranging phase II trial to assess efficacy/safety in patients with mild-to-high hypertriglyceridemia (2014) (0)
Characterization of dyslipidemic French-Canadian patients with double pre-betalipoproteinemia (1994) (0)
Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation 1 (2014) (0)
[Nutritional aspects of managing hyperlipidemias and atherosclerosis]. (1980) (0)
Ongoing clinical trials of the pleiotropic effects (2005) (0)
Assessment of atherosclerosis for genetic analysis - emphasis on clinical expression or pathogenetic mechanism? (1979) (0)
Effects of chlorthalidone and metoprolol alone or in combination (Logroton) on blood pressure, lipids lipoproteins in hypertension (1990) (0)
3FS07-5 NARC-1: A potential new target for drug therapy of hypercholesterolemia (2003) (0)
Gender-specific lipoprotein influence on coronary artery disease in French-Canadian patients with heterozygous familial hypercholesterolemia (1994) (0)
385 – CALCITONIN: A POTENTIAL DIABETOGENIC HORMONE (1978) (0)
[Selective beta blockaders (metoprolol) versus non selective (propranolol): comparative effects on the composition of lipoprotein fractions and on blood pressure]. (1980) (0)
Statins and atherogenic process (2000) (0)
1.P.358 Further characterization of triglyceride-rich lipoproteins from patients affected with pseudo-type III dyslipoproteinemia (1997) (0)
Identification of a γ-IFN responsive element in the promoter of the human macrophage receptor-A gene (2000) (0)
Regulation of liver lipoprotein lipase gene expression (1995) (0)
(J. Am. Coll. Nutr., 02:055-062)Effect of methyl linoleate administration on phospholipid fatty acid composition and osmotic fragility of erythrocyte in essential fatty acid deficient rat (1983) (0)
[The predictive value of apolipoproteins in atheroma]. (1987) (0)
Adenoviral overexpression of AnxA2 in mouse liver significantly increases LDLR levels. (2012) (0)
Cholestyramine tablets, a new option in the treatment of hypercholesterolemia (1994) (0)
Fatty acids as transcriptional regulators of the lipoprotein lipase and apo C-III genes: consequences for plasma triglyceride metabolism (1996) (0)
Clinical expression in heterozygotes of two frequent low density lipoprotein receptor gene mutations in the French Canadian population (1994) (0)

This paper list is powered by the following services:

Other Resources About Jean Davignon

en.wikipedia.org

What Schools Are Affiliated With Jean Davignon?

Jean Davignon is affiliated with the following schools: